It has come to light that there are irregularities in a clinical trial published by The BMJ on 29 October 2025: Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8) .
An expression of concern has been placed on the paper.
Examples of the issues identified include irregularities in the data, concern about the inclusion of participants who did not meet the age criteria specified in the study, and concerns about undeclared conflicts of interest and authorship.
The BMJ’s content integrity team will take up the concerns with the authors, and investigate fully – involving institutions and regulatory authorities as necessary. The BMJ will update this notice and make a decision about what post publication change to the content is needed.
The BMJ